The COVID-19 pandemic demonstrated the need for readily available mRNA vaccines that do not require ultra-cold storage.
UMass, Sepragen and the University of Pennsylvania will create a continuous, automated, compact mRNA producing machine.
To do this, the team will:
All these tasks at the conclusion of the project will be integrated to successfully produce continuous purification platform for Mab production.
This project replaces centralized, cold-chain-dependent batch manufacturing with a compact, automated unit capable of producing thermostabilized mRNA at the point of need. By utilizing inline ultraviolet sensors and feedback algorithms, the system minimizes "out-of-spec" waste, projected to increase process consistency and material utilization by 20–30%. Transitioning to this continuous, decentralized model is estimated to reduce total logistics and facility overhead by 45% by eliminating the need for -80-degree Celsius infrastructure and high-intensity manual labor.
Developed a prototype continuous mRNA producing machine with Integration of inline sensor technology
Yoon, S., Presenter, ARP-09 Rapid Continuous Production of Room Temperature Stable mRNA Vaccines, NIIMBL National Meeting, Washington, D.C., July 28, 2022.
Login to the NIIMBL member portal to access additional project information, including presentations, progress updates, reports, and more.
Not yet a member? Learn more about which level of NIIMBL membership is right for you and your organization.
University of Massachusetts System
Sepragen Corporation
